Why Novavax and Pfizer Are Trouncing the Market Today
On yet more worrying news about the omicron variant of the coronavirus, the fortunes of coronavirus stocks were mixed on Tuesday. Some of the ones doing particularly well in midafternoon trading were Novavax (NASDAQ: NVAX), up nearly 7%, and bellwether Pfizer (NYSE: PFE) with a 2.4% gain.
In contrast the co-developer of Pfizer's jab, BioNTech (NASDAQ: BNTX), was down by almost 3%.
It's interesting that the fortunes of partners Pfizer and BioNTech, which together developed the Comirnaty vaccine, were diverging so sharply.
Source Fool.com
